<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131185">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394185</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00041251</org_study_id>
    <secondary_id>R01DA025044</secondary_id>
    <nct_id>NCT01394185</nct_id>
  </id_info>
  <brief_title>Effects of Dronabinol (Oral THC) on Cannabis Use</brief_title>
  <official_title>Effects of Dronabinol (Oral THC) on Cannabis Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of people seeking treatment for marijuana-related problems is on the rise, yet
      there is no currently accepted medication proven to help them quit. This research is
      designed to determine whether the FDA approved medication dronabinol (MarinolÂ®) has effects
      that might help make it easier for people to stop daily marijuana use, and to carefully
      study the occurence of safety risks and side-effects at different doses of the drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marijuana self-administration</measure>
    <time_frame>up to 39-day hospital stay</time_frame>
    <description>Participants will be able to self-administer marijuana under different study conditions. The amount administered across these conditions is the primary study endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug effect</measure>
    <time_frame>Measured daily during 39-day hospital stay</time_frame>
    <description>Participants will complete assessments regarding subjective drug effects multiple times each day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitals</measure>
    <time_frame>Measured daily during 39-day hospital stay</time_frame>
    <description>Participants will have vitals assessed multiple times each day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Marijuana Smoking</condition>
  <arm_group>
    <arm_group_label>Dronabinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive active dronabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>Participants receive dronabinol</description>
    <arm_group_label>Dronabinol</arm_group_label>
    <other_name>Marinol</other_name>
    <other_name>THC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants receive placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current use of marijuana

          -  Able to give informed consent

        Exclusion Criteria:

          -  Daily use of psychoactive medication

          -  Current Axis I psychiatric disorder other than dependence on cannabis or nicotine, or
             abuse of drugs or alcohol

          -  Women who are pregnant, breast feeding, or planning to become pregnant within the
             next 3 months

          -  Those seeking treatment for cannabis-related problems or using cannabis under the
             guidance of a physician for a medical disorder

          -  Uncontrolled or unstable cardiovascular disease

          -  Allergy to sesame oil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University (Bayview Campus)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 11, 2012</lastchanged_date>
  <firstreceived_date>July 12, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Ryan Vandrey</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>marijuana</keyword>
  <keyword>dronabinol</keyword>
  <keyword>pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
